3BORJESSON P K, POSTEMA E J, ROOS J C, et al. Phase I therapy study with ^186Re-labeled humanized monoclonal antibody BIWA 4(bivatuzumab)in patients with head and neck squamous cell carcinoma [J]. Clin Cancer Res,2003,9(2) :3 961-3 972.
4VEREL I, VISSER G W, BOELLAARD R, et al. Quantitative ^89Zr immuno-PET for in vivo scouting of ^90Y-labeled monoclonal antibodies in xenograft-bearing nude mice [J] .J Nucl Med,2003,44(10) :1 663-1 670.
5WAHL R L. The clinical imlaortance of dosimetry in radioimmunotherapy with tositumomab and iodine I^131 tositumomab[J ]. Semin Oncol,2003,30(4) :31-38.
6DAVISC. Transgenicmice as a source of fully human antibodies for the treatment of cancer [J ]. Cancer Metastasis Rev,1999,18(4) :421-425.
7YANG X D. Fully humanati inter leukin 8 monoclonal antibodies: Potential the repeutics for the treatment of in flammatory disease states [J] .J Leukoc Bio1,1999,66(3) :401-410.
8GEUS B, HENDRIKSEN C F. In vivo and in vitro production of monoclonal antibodies: Current possibilities and future perspectives,introduction [J ]. Res Immunol, 1998,149:533-534.
9FALKENBERG F W. Monoclonal antibody production: Problems and solutions [J ]. Res Immunol, 1998,149:542-547.
10GREEN L. Antibody engineering via genetic engineering of the mouse: Xenomouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies [ J ]. J Immunol Methods, 1999,231 ( 1 - 2) : 11-23.
